FDA approves Freenome SimpleScreen CRC test
September 2026—The FDA has approved Freenome’s SimpleScreen CRC, a blood-based screening test for colorectal cancer in adults 45 and older who are at average risk for developing the disease.
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
FDA clears OraSure at-home urine collection kit on Roche Cobas systems
September 2026—The FDA has cleared OraSure Technologies’ Colli-Pee Dx Urine Collection kit for use with Roche’s tests for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium on the Roche Cobas 5800, 6800, and 8800 molecular diagnostic systems.
Beckman Coulter launches DxU 1800 urinalysis solution
August 2026—Beckman Coulter Diagnostics has launched in the U.S. its DxU 1800 system, a fully automated urinalysis solution that combines the new DxU 1800c chemistry analyzer with a DxU Iris microscopy analyzer.
Diazyme acquires CLC
August 2026—Diazyme Laboratories has acquired Carolina Liquid Chemistries Corp., an FDA-registered manufacturer and reseller of chemistry systems and reagents.
Zepto introduces two FungiFlex tests
August 2026—Zepto Life Technology has introduced FungiFlex Pneumocystis jirovecii, a targeted plasma cell-free DNA liquid biopsy assay for the detection of P. jirovecii, and the FungiFlex Mold Plus panel, which combines invasive mold detection with P. jirovecii in a single plasma-based test order.
Streck gets IVD clearance for controls, launches blood collection tube
August 2026—Streck has received in vitro diagnostic clearance for three MDx-Chex controls for sepsis testing. MDx-Chex for BCY, MDx-Chex for BCP, and MDx-Chex for BCN are patient-like, ready-to-use, full-process molecular quality controls designed for verification of the Diasorin Liaison Plex yeast, Gram-positive, and Gram-negative blood culture assays, respectively. The controls are supplied in 10 single-use vial kits and feature room-temperature storage.
Pictor debuts PictImager at ADLM 2026
August 2026—Pictor Holdings debuted its next-generation high-resolution platform, the PictImager, at the Association for Diagnostics and Laboratory Medicine Annual Meeting and Clinical Lab Expo (July 26–30, Anaheim, Calif.).
Werfen, Oxford Nanopore collaborate
August 2026—Werfen and Oxford Nanopore Technologies have entered a strategic collaboration to validate Werfen’s transplant assay portfolio, including solutions for human leukocyte antigen typing and pretransplant matching, for use on Oxford Nanopore sequencing platforms.
Clarapath launches TrimStar Pro
August 2026—Clarapath launched TrimStar Pro, an FDA-registered facing and trimming solution designed to help histology laboratories take a step toward automation.
From glass archive to AI-ready data sets: Pittsburgh’s approach to large-scale slide digitization
August 2026—At the University of Pittsburgh’s Computational Pathology and AI Center of Excellence (CPACE), artificial intelligence research in disease detection begins with a practical reality: most of the data still lives on glass.